ZVRAHIGH SIGNALFINANCIAL10-K

ZVRA demonstrated a dramatic improvement in operating cash flow burn while substantially expanding its asset base and cash position.

The company's operating cash flow improved dramatically from nearly $70M in outflows to minimal burn of $1.6M, suggesting either significant operational improvements or timing effects that warrant close examination. Combined with the substantial increase in cash reserves and total assets, this indicates either successful capital raising, business model improvements, or favorable working capital dynamics that have meaningfully strengthened the company's financial position.

Comparing 2026-03-09 vs 2025-03-12View on EDGAR →
FINANCIAL ANALYSIS

ZVRA's financial profile improved markedly, with operating cash burn nearly eliminated while cash reserves grew substantially to $62.4M and total assets expanded notably to $284.7M. Operating losses modestly improved despite higher SG&A expenses of $77.6M, while accounts receivable declined and inventory remained relatively stable. The overall picture signals either successful fundraising activities or significant operational improvements that have dramatically enhanced the company's liquidity position and reduced cash burn concerns.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
+97.7%
-$69.7M→-$1.6M

Operating cash flow surged 97.7% — exceptional cash generation, highest quality earnings signal.

Cash & Equivalents
Balance Sheet
+84.7%
$33.8M→$62.4M

Cash position surged 84.7% — strong cash generation or capital raise providing significant financial cushion.

Total Assets
Balance Sheet
+59.8%
$178.1M→$284.7M

Asset base grew 59.8% — expansion through organic growth, acquisitions, or capital deployment.

SG&A Expense
P&L
+41.5%
$54.9M→$77.6M

SG&A up 41.5% — significant increase in sales or administrative costs, monitor impact on operating leverage.

Accounts Receivable
Balance Sheet
-36.9%
$16.1M→$10.2M

Receivables declined — improved collection efficiency or conservative revenue recognition.

Operating Income
P&L
+27.7%
-$87.0M→-$62.9M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Current Liabilities
Balance Sheet
+15.3%
$34.1M→$39.3M

Current liabilities rose 15.3% — increased short-term obligations, watch current ratio.

R&D Expense
P&L
+14.9%
$8.8M→$10.2M

R&D investment increased 14.9% — signals commitment to future product development, though near-term margin impact.

Inventory
Balance Sheet
-11.7%
$2.0M→$1.7M

Inventory reduced 11.7% — lean inventory management or demand outpacing supply.

LANGUAGE CHANGES
NEW — 2026-03-09
PRIOR — 2025-03-12
ADDED
001-36913 ______________________________________________________________________ Zevra Therapeutics, Inc.
A s of March 6, 2026, the registr ant had 58,711,584 shares of common stock outstanding.
Management's Discussion and Analysis of Financial Condition and Results of Operations 55 Item 7A.
The outcomes of the events described in these forward-looking statements are subject to risks, uncertainties and other factors described in Risk Factors and elsewhere in this report.
These risks are discussed more fully in the section titled Risk Factors .
+7 more — sign up free →
REMOVED
A s of March 7 , 2025, the registrant had 54,115,869 shares of common stock outstanding.
Management's Discussion and Analysis of Financial Condition and Results of Operations 82 Item 7A.
The outcome of the events described in these forward-looking statements is subject to risks, uncertainties and other factors described in Risk Factors and elsewhere in this report.
These risks are discussed more fully in the section titled "Risk Factors".
Material risks that may affect our business, financial condition, results of operations, and trading price of our common stock include the following: If commercialization of our approved products, or any of our product candidates, if approved, are not successful, or we experience significant delays in commercialization, our business will be harmed.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →